Sigma Planning Corp’s AbbVie ABBV Stock Holding History

Sigma Planning Corp’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.1M	Sell	55,986 -840	-1%	-$181K	0.35%	44
2026 Q1	$12.4M	Sell	56,826 -2,478	-4%	-$550K	0.34%	48
2025 Q4	$13.6M	Buy	59,304 +383	+0.7%	+$87.2K	0.37%	42
2025 Q3	$13.6M	Sell	58,921 -42,829	-42%	-$8.72M	0.39%	39
2025 Q2	$18.9M	Sell	101,750 -4,396	-4%	-$817K	0.57%	25
2025 Q1	$22.2M	Sell	106,146 -992	-0.9%	-$193K	0.71%	18
2024 Q4	$19M	Sell	107,138 -2,324	-2%	-$427K	0.6%	22
2024 Q3	$21.6M	Sell	109,462 -987	-0.9%	-$184K	0.66%	20
2024 Q2	$18.9M	Sell	110,449 -14,051	-11%	-$2.33M	0.6%	20
2024 Q1	$22.7M	Buy	124,500 +47,145	+61%	+$8.13M	0.71%	17
2023 Q4	$12M	Sell	77,355 -49,803	-39%	-$7.26M	0.94%	15
2023 Q3	$19M	Buy	127,158 +34,586	+37%	+$5.08M	0.71%	19
2023 Q2	$12.5M	Sell	92,572 -10,125	-10%	-$1.48M	0.45%	35
2023 Q1	$16.4M	Sell	102,697 -3,621	-3%	-$554K	0.54%	27
2022 Q4	$17.2M	Sell	106,318 -171	-0.2%	-$26.2K	0.61%	23
2022 Q3	$14.3M	Buy	106,489 +2,922	+3%	+$419K	0.54%	27
2022 Q2	$15.9M	Sell	103,567 -21,878	-17%	-$3.34M	0.55%	26
2022 Q1	$20.3M	Sell	125,445 -3,579	-3%	-$520K	0.61%	26
2021 Q4	$17.5M	Buy	129,024 +4,851	+4%	+$573K	0.49%	35
2021 Q3	$13.4M	Buy	124,173 +910	+0.7%	+$104K	0.4%	44
2021 Q2	$13.9M	Buy	123,263 +8,588	+7%	+$967K	0.41%	42
2021 Q1	$12.4M	Sell	114,675 -6,795	-6%	-$727K	0.4%	46
2020 Q4	$13M	Buy	121,470 +3,554	+3%	+$342K	0.44%	40
2020 Q3	$10.3M	Buy	117,916 +7,886	+7%	+$742K	0.41%	45
2020 Q2	$10.8M	Buy	110,030 +26,754	+32%	+$2.36M	0.47%	35
2020 Q1	$6.34M	Sell	83,276 -104	-0.1%	-$8.86K	0.38%	45
2019 Q4	$7.38M	Buy	83,380 +5,091	+7%	+$423K	0.31%	55
2019 Q3	$5.93M	Buy	78,289 +6,323	+9%	+$434K	0.28%	66
2019 Q2	$5.23M	Buy	71,966 +6,095	+9%	+$479K	0.27%	79
2019 Q1	$5.31M	Buy	65,871 +8,731	+15%	+$714K	0.3%	74
2018 Q4	$5.27M	Sell	57,140 -8,833	-13%	-$777K	0.38%	59
2018 Q3	$6.24M	Buy	65,973 +3,630	+6%	+$344K	0.37%	54
2018 Q2	$5.78M	Buy	62,343 +4,929	+9%	+$481K	0.39%	50
2018 Q1	$5.43M	Buy	57,414 +976	+2%	+$107K	0.4%	54
2017 Q4	$5.46M	Buy	56,438 +1,167	+2%	+$110K	0.42%	47
2017 Q3	$4.91M	Buy	55,271 +648	+1%	+$49.3K	0.41%	49
2017 Q2	$3.96M	Buy	54,623 +558	+1%	+$37.5K	0.37%	51
2017 Q1	$3.52M	Buy	54,065 +5,326	+11%	+$335K	0.34%	58
2016 Q4	$3.05M	Buy	48,739 +5,642	+13%	+$344K	0.33%	56
2016 Q3	$2.72M	Buy	43,097 +1,513	+4%	+$97.9K	0.32%	64
2016 Q2	$2.57M	Sell	41,584 -33,339	-44%	-$2.03M	0.34%	60
2016 Q1	$4.28M	Buy	74,923 +1,821	+2%	+$101K	0.59%	34
2015 Q4	$4.33M	Buy	73,102 +3,345	+5%	+$193K	0.61%	32
2015 Q3	$3.8M	Sell	69,757 -1,292	-2%	-$84.1K	0.6%	26
2015 Q2	$4.77M	Buy	71,049 +2,772	+4%	+$181K	0.66%	21
2015 Q1	$4M	Buy	68,277 +2,839	+4%	+$172K	0.53%	31
2014 Q4	$4.28M	Buy	+65,438	New	+$4.13M	0.57%	32

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Sigma Planning Corp's ABBV Position: Q2 2026 in Review

Sigma Planning Corp reduced its AbbVie (ABBV) stake by 1.5% in Q2 2026, selling an estimated $181K and leaving 55,986 shares worth $14.1M. The position accounts for 0.35% of the portfolio, ranked #44.

Sigma Planning Corp first reported a position in ABBV in Q4 2014 and has held it in 47 quarters since. The position peaked at $22.7M in Q1 2024. 2,841 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Sigma Planning Corp held 55,986 shares of AbbVie worth $14.1M as of Q2 2026.
Sigma Planning Corp sold 840 AbbVie shares in Q2 2026, an estimated $181K.
AbbVie made up 0.35% of Sigma Planning Corp's portfolio in Q2 2026, its #44 holding.
Sigma Planning Corp first reported a position in AbbVie in Q4 2014 and has held it in 47 quarters since.
Sigma Planning Corp's AbbVie position peaked at $22.7M in Q1 2024.
2,841 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sigma Planning Corp's 13F filing for Q2 2026, filed 7 Aug 2026.